* Download the : Registration Form
After this webinar attendees will be able to answer
Webinar details
Clinical manufacturing presents one of the most difficult quality challenges in pharmaceutical development. Commercial manufacturing typically operates with established formulations, validated processes, mature analytical methods, approved specifications, defined stability programs, and substantial manufacturing knowledge. Clinical manufacturing is different: the product, process, analytical methods, specifications, formulation, presentation, stability data, and manufacturing knowledge may all still be changing.
The challenge is not whether GMPs apply during clinical manufacturing. The more difficult question is how much control is appropriate at a particular stage of development—and whether the organization can defend the decisions it makes.
This program focuses on applying GMP principles in a changing clinical-development environment without treating early manufacturing exactly like a mature commercial operation. It examines where flexibility may be appropriate, where stronger controls remain necessary, how product and process knowledge develops over time, how testing and specifications evolve, how expiry dating is established, and when manufacturing elements need to become increasingly fixed as development advances.
For Quality Assurance, Quality Control, Compliance, Regulatory Affairs, CMC, and Manufacturing leaders, the central issue is defensibility. When an auditor, inspector, regulatory reviewer, or executive asks why a particular level of control was considered sufficient at that stage of development, the organization should be able to point to a scientifically sound, risk-based rationale—not merely to the fact that the batch was clinical.
Important 2026 FDA Update: Phase 1 CMC Flexibility
FDA has recently clarified CMC flexibilities for First-in-Human (FIH) Phase 1 INDs. FDA explains that some sponsors have historically submitted more CMC information than necessary at the FIH Phase 1 stage, which can create unnecessary work and delay development. The Agency is emphasizing phase-appropriate requirements: enough CMC information to support product quality and patient safety without requiring information that can appropriately be generated later.
Examples of areas where FDA identifies potential early-phase flexibility include the amount of stability data submitted, the extent of analytical method validation, and certain process controls that are not directly related to product safety. FDA nevertheless continues to require sufficient information throughout the IND lifecycle to assure the investigational drug’s identity, quality, purity, and strength.
FDA states that focusing on phase-appropriate CMC requirements could reduce FIH Phase 1 IND development time by up to 12 months. This does not mean Phase 1 products are exempt from GMP expectations; rather, it makes scientific justification, risk assessment, Quality oversight, and documentation even more important.
Additional 2026 Quality Update: ICH Q8/Q9/Q10 R5
FDA finalized the Q8, Q9 and Q10 Questions and Answers (R5) in May 2026, providing current clarification on Pharmaceutical Development (Q8), Quality Risk Management (Q9), and Pharmaceutical Quality Systems (Q10).
This is highly relevant to clinical manufacturing because it reinforces risk-based decision-making while organizations are still building product and process knowledge. The practical compliance question is whether regulatory flexibility is being driven by documented science and risk—or merely by schedule and cost pressure.
Regulatory Framework Covered / Relevant
This webinar benefits the following agencies / organizations
Who should attend?